Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06106360 · ClinicalTrials.gov registry record
A Pilot Prospective Clinical Trial Using Remote Monitoring for Cancer Patients Undergoing Outpatient Chemotherapy
A clinical trial of Solid Tumor and Hematological Malignancy, sponsored by Inova Health Care Services.
- Recruiting
- Registry status
- 100
- Enrollment target
- 1
- Study location
NCT06106360 is a study of Solid Tumor and Hematological Malignancy that is actively recruiting participants, run by Inova Health Care Services. The registered enrollment target is 100 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (55% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06106360, a study of Solid Tumor and Hematological Malignancy, is actively recruiting participants, sponsored by Inova Health Care Services.
- RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
A pilot study using remote monitoring technology developed by Locus Health in cancer patients undergoing chemotherapy treatment.
Conditions Studied
Interventions
- DEVICE Locus Health iPhone App
Study Locations (1)
Virginia
- Inova Schar Cancer Institute - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2023-10-26 |
| Est. Completion | 2026-06-26 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06106360
The ClinicalTrials.gov registry entry for NCT06106360 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (55% lower). The listed sponsor is Inova Health Care Services, which has 75 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which Locus Health iPhone App is the first listed.
NCT06106360 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.
Frequently Asked Questions
What is clinical trial NCT06106360 about?
NCT06106360 is a clinical study titled "A Pilot Prospective Clinical Trial Using Remote Monitoring for Cancer Patients Undergoing Outpatient Chemotherapy". A pilot study using remote monitoring technology developed by Locus Health in cancer patients undergoing chemotherapy treatment.
What is the current status of trial NCT06106360?
This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2023-10-26. Estimated completion is 2026-06-26.
What conditions does trial NCT06106360 study?
This clinical trial studies the following conditions: Solid Tumor, Hematological Malignancy.
What interventions are being tested in trial NCT06106360?
The interventions under investigation include: Locus Health iPhone App (DEVICE).
Who is sponsoring clinical trial NCT06106360?
This trial is sponsored by Inova Health Care Services, which has 75 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06106360 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
RECRUITING · Phase 2
-
Dabrafenib and/or Trametinib Rollover Study
RECRUITING · Phase 4
-
An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
RECRUITING · Phase 3
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.